RPI.4610 in Treating Patients With Metastatic Kidney Cancer

Completed · Phase 2

Conditions studied: Kidney Cancer

In brief

RATIONALE: RPI.4610 may stop the growth of metastatic kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patients who have metastatic kidney cancer.

Key facts

Study ID

NCT00021021

Run by

Ribozyome

Starts

2001-09-01

Expected to finish

2004-02-01

Last updated by the study team

2013-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.